SCNI BiondVax Pharmaceuticals: Bathi resik saben saham sajrone 12 wulan pungkasan

High dependence on the success of a narrow range of vaccines creates serious threats for Scinai Immunotherapeutics (SCNI). However, a flexible nanobody platform accelerates the transition of new formulas to testing. Meanwhile, the lack of revenue and R&D expenses are weighing on capital. The rolling annual EPS change indicator demonstrates fundamental stability dynamics, where 94.40 describes the current status of the metric.
SCNI (scinai.com): rincian analitis lan laporan miturut indikator

This indicator calculates the percentage change in earnings per share over the last four quarters relative to the same period last year. This metric neutralizes seasonality, demonstrating the true efficiency of profit generation. For Scinai Immunotherapeutics (SCNI), such fluctuations often reflect the costs of developing biologics in partnership with immunology centers. By analyzing the annual volatility of TTM net income per share, an investor can see the impact of R&D expenses on profitability.